glp 1 nature GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Naturally optimize your appetite Glucagon-like peptide 1 receptor agonists:

New treatments, including GLP-1 medications like Ozempic, have offered hope to many for weight management and diabetes control

Since, studies have attempted to elucidate the mechanisms governing this reduction and further identify the clinical utility of GLP-1RAs, but much must be inferred from preclinical studies in diabetic models

Merck didn't respond to requests for comment in time for publication

Fulltext Views 332,786 PDF downloads 56,604

Decades of rodent work do not transfer into a clinical recommendation by default

Cosmos Study October 14, 2025 Dual-Team Study Team A:Kersten Bartelt, RNEric Barkley Team B:Joel Jones, PharmDJoe Deckert, PhD Key Findings Among non-diabetic patients without chronic kidney disease (CKD), there was a minimal increase of 0.01 mg/dL to 0.02 mg/dL in serum creatinine in the months following initiation of semaglutide, liraglutide, or tirzepatide